Adding interferon to ruxolitinib for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of myelofibrosis (including post-polycythemia vera or post-essential thrombocythemia).
- You have been taking ruxolitinib for at least 3 months, with a stable dose for the last 6 weeks.
- Your spleen is enlarged (at least 450 mL as measured by scan).
- You have a specific genetic mutation (JAK2, CALR, or MPL) with a burden of at least 20%.
- You are generally in good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.